troglitazone has been researched along with Genetic Predisposition in 6 studies
Troglitazone: A chroman and thiazolidinedione derivative that acts as a PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS (PPAR) agonist. It was formerly used in the treatment of TYPE 2 DIABETES MELLITUS, but has been withdrawn due to hepatotoxicity.
| Excerpt | Relevance | Reference |
|---|---|---|
| " The objective of this study was to examine the impact of chronic use of an insulin sensitizer on glucose metabolism in normal glucose tolerant AA at risk for DM (previous gestational diabetes mellitus [GDM] or first-degree relative with DM)." | 2.71 | The impact of an insulin sensitizer, troglitazone, on glucose metabolism in African Americans at risk for type 2 diabetes mellitus: a placebo-controlled, 24-month randomized study. ( Gaillard, T; Habash, D; Osei, K; Rhinesmith, S; Schuster, D, 2003) |
| "There is evidence that one of the key type 2 diabetes (T2D) loci identified by GWAS exerts its influence early on in life through its impact on pediatric BMI." | 1.38 | Expression analyses of the genes harbored by the type 2 diabetes and pediatric BMI associated locus on 10q23. ( Aziz, AR; Deliard, S; Grant, SF; Zhao, J, 2012) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 5 (83.33) | 29.6817 |
| 2010's | 1 (16.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Moore, AF | 1 |
| Jablonski, KA | 1 |
| Mason, CC | 1 |
| McAteer, JB | 1 |
| Arakaki, RF | 1 |
| Goldstein, BJ | 1 |
| Kahn, SE | 1 |
| Kitabchi, AE | 1 |
| Hanson, RL | 1 |
| Knowler, WC | 1 |
| Florez, JC | 1 |
| Zhao, J | 1 |
| Deliard, S | 1 |
| Aziz, AR | 1 |
| Grant, SF | 1 |
| Schuster, D | 1 |
| Gaillard, T | 1 |
| Rhinesmith, S | 1 |
| Habash, D | 1 |
| Osei, K | 1 |
| Hug, H | 1 |
| Dannecker, R | 1 |
| Schindler, R | 1 |
| Bagatto, D | 1 |
| Stephan, A | 1 |
| Wess, RA | 1 |
| Gut, J | 1 |
| Ikeda, T | 1 |
| Jin, M | 1 |
| Takahashi, M | 1 |
| Moto, M | 1 |
| Muguruma, M | 1 |
| Ito, K | 1 |
| Watanabe, K | 1 |
| Kenmochi, Y | 1 |
| Kono, T | 1 |
| Hasumi, K | 1 |
| Mitsumori, K | 1 |
2 reviews available for troglitazone and Genetic Predisposition
| Article | Year |
|---|---|
Ontology-based knowledge management of troglitazone-induced hepatotoxicity.
Topics: Adverse Drug Reaction Reporting Systems; Antineoplastic Agents; Chemical and Drug Induced Liver Inju | 2004 |
[Drug-induced liver injury].
Topics: Acetaminophen; Anesthetics, General; Animals; Benzoquinones; Chemical and Drug Induced Liver Injury; | 2006 |
2 trials available for troglitazone and Genetic Predisposition
| Article | Year |
|---|---|
The association of ENPP1 K121Q with diabetes incidence is abolished by lifestyle modification in the diabetes prevention program.
Topics: Chromans; Combined Modality Therapy; Diabetes Mellitus, Type 2; Exercise Therapy; Female; Gene Frequ | 2009 |
The impact of an insulin sensitizer, troglitazone, on glucose metabolism in African Americans at risk for type 2 diabetes mellitus: a placebo-controlled, 24-month randomized study.
Topics: Adult; Black People; Blood Glucose; Body Constitution; Body Mass Index; C-Peptide; Chromans; Diabete | 2003 |
2 other studies available for troglitazone and Genetic Predisposition
| Article | Year |
|---|---|
Expression analyses of the genes harbored by the type 2 diabetes and pediatric BMI associated locus on 10q23.
Topics: Adipocytes; Adipogenesis; Arrhythmias, Cardiac; Body Mass Index; Cell Line; Chromans; Chromosomes, H | 2012 |
Carcinogenic susceptibility of rasH2 mice to troglitazone.
Topics: Adipose Tissue, Brown; Administration, Oral; Animals; Carcinogenicity Tests; Chromans; Dose-Response | 2007 |